

RÉSUMÉ DIGEST

ACT 294 (HB 435)

2023 Regular Session

Freeman

New law defines "chimeric antigen receptor (CAR) T-cell therapy" and references the definition of "healthcare facility" as provided in existing law.

New law requires the La. Medicaid program to provide inpatient and, if appropriate, outpatient coverage for CAR T-cell therapy when such therapy has been approved by the U.S. Food and Drug Administration, is used for a medically accepted indication, and is administered in a healthcare facility appropriately providing CAR T-cell therapy in accordance with state and federal guidelines or certifications.

New law requires a healthcare facility appropriately providing CAR T-cell therapy in accordance with state and federal guidelines or certifications to participate in the La. Medicaid program to provide CAR T-cell therapy to eligible enrollees, as defined in new law.

New law requires a healthcare facility appropriately providing CAR T-cell therapy in accordance with state and federal guidelines or certifications to make a determination of a prospective enrollee's eligibility for CAR T-cell therapy enrollment.

New law establishes the following requirements for a prospective enrollee to be considered eligible for CAR T-cell therapy enrollment:

- (1) The individual is enrolled in the La. Medicaid program.
- (2) A licensed healthcare provider has certified that CAR T-cell therapy is medically necessary and appropriate to treat the individual's condition.
- (3) The CAR T-cell therapy is administered in a healthcare facility appropriately providing CAR T-cell therapy in accordance with state and federal guidelines or certifications.

New law requires the secretary of the La. Dept. of Health to do all of the following:

- (1) Submit to the Centers for Medicare and Medicaid Services all necessary state plan amendments.
- (2) Promulgate all necessary rules and regulations in accordance with existing law.
- (3) Promulgate rules as necessary to regulate and provide payment to healthcare providers for high cost pharmaceutical carve-outs in accordance with the provisions of new law.
- (4) Take any other actions necessary to implement the provisions of new law.

Effective August 1, 2023.

(Adds R.S. 40:1258.1 and 1258.2)